Unlocking the health benefits of cannabinoids.

Sanity Group GmbH, one of Germany’s leading cannabis companies, announced the completion of an investment from the Jupiter Fund of Organigram Holdings Inc., a leading licensed cannabis producer based in Toronto, Canada, today. This marks Organigram’s first investment in the European cannabis market. Using funds from the Jupiter Fund, the Canadian producer is investing 14 million euros in the form of a convertible loan into Sanity Group. Additionally, the company has the option to call for a second tranche of three million euros as part of the convertible loan. Simultaneously with the investment, Organigram and Sanity Group have agreed on a new supply agreement to deepen their partnership, which has been in place since 2023.

With the passage through the Federal Council, the planned partial legalization of cannabis in Germany has successfully cleared the final parliamentary hurdle today: The Cannabis Act “CanG” (Pillar 1) officially comes into effect on April 1st, as the convocation of the compromise committee did not materialize. In today’s vote, a minority advocated for a compromise committee, while the majority abstained or voted against. For the German cannabis industry, this marks an important, albeit only initial step, states Finn Hänsel, founder and CEO of the Berlin-based cannabis company Sanity Group: “The foundation for the decriminalization and destigmatization of consumers, but above all, for better patient care with medicinal cannabis, has been laid today. Now the real work begins.” A timely implementation of the second pillar of CanG is now essential. In the medical context, due to the removal of cannabis from the Narcotics Act, a significant increase in the number of patients is expected, as access to this form of therapy is significantly simplified.